Trump administration action reported: White House adviser Dr. Heidi Overton named as nominee for FDA commissioner

President Donald Trump named Dr. Heidi Overton as his nominee to be commissioner of the Food and Drug Administration, according to an announcement reported by The Hill on Wednesday. The report says the nomination was posted by the president to Truth Social and that Overton is a physician and a senior White House domestic policy adviser focused on health issues.

The FDA commissioner is the agency’s top leadership role and the position typically confirmed by the Senate. If confirmed, Overton would replace the current commissioner leadership structure and take responsibility for FDA’s regulatory and enforcement functions covering pharmaceuticals, medical devices, food and dietary supplements, and aspects of public health safety.

The Hill reported that the FDA has been “roiled” by an exodus of top staff, an environment that would make the commissioner slot particularly consequential for continuity in management and for moving ongoing regulatory work through the agency’s pipeline. Under that scenario, a confirmed commissioner would be expected to set priorities across drug and device review policies, compliance and enforcement, and guidance development.

Beyond the commissioner vacancy question, FDA’s day-to-day regulatory activity continues through Federal Register rulemakings. On August 19, the Federal Register published an FDA final rule amending food-additive regulations for use of chromium DL-methionine chelate as a nutritional source of chromium in cattle feed, in response to a petition filed by Zinpro Corp. The Federal Register also posted a draft guidance on August 18 intended to help applicants determine whether to submit an Abbreviated New Drug Application (ANDA) or a 505(b)(2) application.

In addition, White House materials posted earlier in August described the administration’s broader focus on prescription-drug pricing, including a claimed record annual decline in drug prices tied to the administration’s Most Favored Nation policies. While those pricing initiatives are not specific to a commissioner choice in the public record cited here, a new FDA commissioner would be positioned to oversee how FDA and related review processes support implementation of such policies.

A Senate confirmation would be the next step for the Overton nomination, after which FDA’s leadership transition would move from reported intent to an operational command role. The practical impact would depend on what FDA leadership prioritizes for regulatory timelines, staffing stability, and implementation of existing rulemakings and guidance already posted to the Federal Register.